Early Clinical Outcome and Doppler Echocardiographic Data after Cardiac Valve Replacement with the ATS prosthesis.
- Author:
Kay Hyun PARK
1
;
Seung Woo PARK
;
Jung Woo YOO
;
Yang Ku YUN
;
Kwhan Mien KIM
;
Tae Gook JUN
;
Jhin Gook KIM
;
Young Mog SHIM
;
Pyo Won PARK
;
Hurn CHAE
;
Won Ro LEE
Author Information
1. Department of Thoracic and Cardiovascular Surgery, Samsung Medical Center, Korea.
- Publication Type:Original Article
- Keywords:
Heart valve prosthesis;
Echocardiography, doppler
- MeSH:
Aortic Valve;
Carbon;
Echocardiography*;
Echocardiography, Doppler;
Endocarditis;
Follow-Up Studies;
Heart Valve Prosthesis;
Heart Valves*;
Hemodynamics;
Humans;
Hypertension;
Intracranial Hemorrhages;
Prostheses and Implants*;
Reoperation;
Retrospective Studies;
Rupture
- From:The Korean Journal of Thoracic and Cardiovascular Surgery
1997;30(7):663-669
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
This is a report on the clinical outcome and hemodynamic profile of the ATS(R) cardiac valve prosthesis, which is a recently introduced pyrolytic carbon bileaflet prosthesis. We retrospectively reviewed the early outcome of 100 consecutive patients who underwent isolated cardiac valve replacement with the ATS(R) prosthesis from October 1994 through June 1996 at our hospital. All patients were evaluated with Doppler echocardiography before discharge from the hospital. The mean age of the patients was 48.6 years(range: 2 to 74). A total of 124 prosthesis were implanted; 71 mitral, 46 aortic, and 7 tricuspid. The two most frequently used sizes were 27 mm(40.8%) and 29 mm(35.2%) in the mitral position, and 23 mm(30.4%) and 21 mm(28.3%) in the aortic position. There was no early or late death. The total follow-up period was 950 patient-months with 99% follow-up rate. Serious late morbidity occurred in three patients; reoperation in two patients for late rupture of Sinus of Valsava in one and for endocarditis with prosthetic dehiscence in the other, and intracranial hemorrhage due to hypertension in one patient. There has been no thromboembolic complication or structural valve deterioration. In the mitral position, the average values of peak and mean transprosthetic pressure gradients and valve area calculated from pressure half time were 6.9+/-2.8 mmHg, 2.6+/-1.5 mmHg, and 2.7+/-0.8 cm2 respectively. In the aortic position, the peak and mean pressure gradients were 26.4+/-15.9 mmHg and 14.2+/-7.9 mmHg. For the mitral prostheses larger than 25-mm size, there was no significant difference among prosthetic sizes in terms of transprosthetic gradients, whereas there was a significant negative correlation between the prosthesis size and the transprosthetic gradients for the aortic valves. The peak and mean pressure gradients were 52.2+/-17.6 mmHg and 26.9+/-7.4 mmHg across the 19-mm aortic prostheses, and 27.1+/-11.9 mmHg and 13.3+/-6.6 mmHg across the 21-mm size. Above results can lead to the conclusion that the early clinical outcome of the ATS valve prosthesis is quite satisfactory. And the hemodynamic characteristics are comparable, if not better, with other bileaflet prostheses.
